Publications by authors named "Paul Covington"

Claim this Profile
E
Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials.
Anthony J Lembo, Paul S Covington, Leonard S Dove, David A Andrae

Neurogastroenterol Motil· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Lai.
Brooks D Cash, Brian E Lacy, Philip S Schoenfeld, Leonard S Dove, Paul S Covington

Am J Gastroenterol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials.
Brian E Lacy, Lucinda A Harris, Lin Chang, Susan Lucak, Catherine Gutman, Paul S Covington

Therap Adv Gastroenterol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Eluxadoline Effect on Cardiac Repolarization.
Laura Bonifacio, Thomas L Hunt, Gail McIntyre, Leonard S Dove, Paul S Covington

Clin Pharmacol Drug Dev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.
Thomas C Marbury, Jolene Kay Berg, Leonard S Dove, Paul S Covington

J Clin Pharmacol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder.
Brooks D Cash, Brian E Lacy, Philip S Schoenfeld, Leonard S Dove, Paul S Covington

Am J Gastroenterol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Croteau and Barkin.
Brooks D Cash, Brian E Lacy, Philip S Schoenfeld, Leonard S Dove, Paul S Covington

Am J Gastroenterol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
Reginald V Fant, Jack E Henningfield, Brooks D Cash, Leonard S Dove, Paul S Covington

Clin Gastroenterol Hepatol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.
Brian E Lacy, William D Chey, Brooks D Cash, Anthony J Lembo, Leonard S Dove, Paul S Covington

Am J Gastroenterol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.
Brian E Lacy, William D Chey, Brooks D Cash, Anthony J Lembo, Leonard S Dove, Paul S Covington

Am J Gastroenterol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
Brooks D Cash, Brian E Lacy, Philip S Schoenfeld, Leonard S Dove, Paul S Covington

Am J Gastroenterol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sphincter of Oddi Function and Risk Factors for Dysfunction.
Elham Afghani, Simon K Lo, Paul S Covington, Brooks D Cash, Stephen J Pandol

Front Nutr· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
Anthony J Lembo, Brian E Lacy, Marc J Zuckerman, Ron Schey, Leonard S Dove, Paul S Covington

N Engl J Med· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.
J Michael Davenport, Paul Covington, Laura Bonifacio, Gail McIntyre, Jürgen Venitz

J Clin Pharmacol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndrome.
David A Andrae, Paul S Covington, Donald L Patrick

Clin Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients.
David A Andrae, Donald L Patrick, Douglas A Drossman, Paul S Covington

Health Qual Life Outcomes· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia.
Paul S Covington, J Michael Davenport, David A Andrae, Martin E Stryjewski, Lisa L Turner

J Antimicrob Chemother· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Leonard S Dove, Anthony Lembo, Charles W Randall, Ronald Fogel, David Andrae, Paul S Covington

Gastroenterology· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2.
J Michael Davenport, Paul Covington, Mark Gotfried, Matthew Medlock, Prapoch Watanalumlerd

Clin Pharmacol Drug Dev· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection.
Paul Covington, J Michael Davenport, David Andrae, William O'Riordan, Lisa Liverman

Antimicrob Agents Chemother· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Paul Covington, Ronald Christopher, Michael Davenport, Penny Fleck, Qais A Mekki

Clin Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Ronald Christopher, Paul Covington, Michael Davenport, Penny Fleck, Qais A Mekki

Clin Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethics and industry-sponsored research.
Chris Kuebler, Walter S Nimmo, RickenbachJosephH von, Dennis Gillings, Allan T Morgan, Paul S Covington

CMAJ· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis